Unlock instant, AI-driven research and patent intelligence for your innovation.

Artificially engineered angiogenesis regulatory system

A technology of artificial manipulation and new blood vessels, applied in the direction of angiogenin, angiogenesis factors, cardiovascular system diseases, etc., can solve the problems of no treatment for cancer metastasis or cancer, and no fundamental method for treating such diseases

Pending Publication Date: 2019-06-04
ツールジェンインコーポレイテッド +3
View PDF8 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, in the conventional technique, initially, it seems that the formation of new blood vessels is suppressed, and then there is a side effect that cancer cells become more aggressive because the pathway of anticancer agents targeting cancer cells is also suppressed
[0005] Therefore, while various studies are underway on the treatment of diseases induced by neovascularization, there are few fundamental treatments for such diseases
[0006] In particular, there is no cure for serious diseases such as cancer metastasis or cancer caused by neovascularization, blindness caused by retinal or corneal degeneration, so it is urgent to develop such fundamental methods to treat neovascularization-related diseases

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Artificially engineered angiogenesis regulatory system
  • Artificially engineered angiogenesis regulatory system
  • Artificially engineered angiogenesis regulatory system

Examples

Experimental program
Comparison scheme
Effect test

Embodiment approach

[1128] As an embodiment of the subject of the present invention, a subject containing a target gene or nucleic acid that guides the nucleic acid-editing protein complex will be described below.

[1129] Here, the target gene may be a factor related to neovascularization, such as VEGFA gene, HIF1A gene, ANGPT2 gene, EPAS1 gene and / or ANGPTL4 gene.

[1130] The target gene can be wild-type or a modified form of the wild-type.

[1131] In an exemplary embodiment of the present invention, the subject may comprise a gene or nucleic acid manipulated by the guide nucleic acid-editing protein complex.

[1132] Here, the manipulated gene may be a factor related to neovascularization, such as VEGFA gene, HIF1A gene, ANGPT2 gene, EPAS1 gene and / or ANGPTL4 gene.

[1133] Here, the guide nucleic acid can target neovascularization-related factors, such as VEGFA gene, HIF1A gene, ANGPT2 gene, EPAS1 gene and / or ANGPTL4 gene.

[1134] The guide nucleic acid can be a nucleic acid sequence com...

Embodiment

[1336] Hereinafter, the present invention will be described in more detail with reference to Examples.

[1337] These examples are provided only to describe the present invention in more detail, and it is obvious to those skilled in the art that the scope of the present invention is not limited to the following examples.

[1338] experimental method

[1339] 1. Design of sgRNA

[1340] Using CRISPR RGEN Tools (Institute of Basic Science, Korea), the CRISPR / Cas9 target regions of the following genes were selected: human VEGFA gene (NCBI accession number NM_001025366.2), HIF1A gene (NCBI accession number NM_001243084.1), ANGPT2 gene (NCBI accession number NM_001118887.1), EPAS1 gene (NCBI accession number NM_001430.4) and ANGPTL4 gene (NCBI accession number NM_001039667.2). Depending on the type of CRISPR enzyme, the target region of the gene can be different. The gene target sequences for CjCas9 are summarized in Table 1-Table 5 and Table 6-Table 9 listed above, and the ge...

example 1

[1430] Example 1. Confirmation of CjCas9 Expression by AAV in Mouse Retinal Tissue

[1431] Since CjCas9 consisting of 984 amino acids has a much smaller size than SpCas9 (2.95 kbp), both the CjCas9 gene and sgRNA can be packaged in one AAV vector. Therefore, in this example, in order to confirm the possibility of genetic manipulation using CjCas9 as a method for treating AMD, AAV expressing CjCas9 was used.

[1432] In order to confirm the expression of CjCas9 by AAV in mouse tissues (such as retina), under the control of U6 promoter-induced sgRNA and choroidal neovascularization (CNV)-related Vegfa gene and Hif1a gene-specific EFS promoter, construct AAV9 vector encoding CjCas9, where CjCas9 was C-terminally linked to eGFP using a self-cleaving T2A peptide (Figure 1A and Figure 1B). The constructed virus was injected into the eyeball by intravitreal injection, and after 6 weeks, CjCas9 expression in the eyeball was confirmed, indel frequency was measured using targeted de...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention relates to artificially engineered angiogenesis-related factors and a use thereof, for angiogenesis regulation. More specifically, the present invention relates to a system thatcan artificially regulate angiogenesis, including artificially engineered angiogenesis-related factors to regulate angiogenesis and / or a composition capable of artificially engineering angiogenesis-related factors. In specific aspects, the present invention relates to artificially engineered angiogenesis-related factors such as VEGFA, HIF1A, ANGPT2, EPAS1, ANGPTL4, etc. and / or an angiogenesis regulatory system by their expression products thereof.

Description

technical field [0001] The present invention relates to artificially manipulated neovascularization-related factors for regulating neovascularization and uses thereof. More specifically, the present invention relates to a system capable of artificially regulating neovascularization, the system comprising artificially manipulated neovascularization-related factors for regulating neovascularization and / or capable of artificial manipulation of neovascularization-related factors Compositions. Background technique [0002] The excessive neovascularization found in many cases of serious disease occurs in diseases such as cancer, macular degeneration, diabetic retinopathy, arthritis and psoriasis. In this state, new blood vessels are supplied to the diseased tissue, resulting in the destruction of normal tissue, and in the case of cancer, the new blood vessels allow tumor cells to enter the circulatory system and thereby colonize another organ (tumor metastasis). [0003] In part...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C12N15/86C12N15/10C12N15/113C12N15/90C12N9/22C07K14/47C07K14/475C07K14/515A61K48/00
CPCC07K14/515C12N9/22C12N15/113C12N15/1136C07K14/52C07K14/4702A61K48/005A01K2227/105A01K2267/03C12N2310/20A61K38/465C12N2750/14143A61P27/02A61P43/00A61P9/00Y02A50/30A61K48/00C07K14/475C12N15/102C12N15/86C12N15/907C12N2310/10A61K9/0048C12N15/11
Inventor 金正勋朴性昱金奭中宋东佑
Owner ツールジェンインコーポレイテッド